Plasmodium falciparum phosphatidylinositol 4-kinase type III beta (PfPI4KIIIβ)

Plasmodium falciparum phosphatidylinositol 4-kinase type III beta (PfPI4KIIIβ) is an essential lipid kinase found in Plasmodium species that catalyzes the phosphorylation of phosphatidylinositol to generate phosphatidylinositol 4-phosphate (PI4P)[1][5][8]. This enzyme is crucial for multiple stages of the malaria parasite lifecycle, mediating membrane trafficking events at the Golgi, which are vital for the formation of new plasma membranes during parasite replication and for the completion of both asexual and sexual developmental stages[1][6]. PfPI4KIIIβ has been validated as a druggable antimalarial target, with several selective inhibitors demonstrating potent activity against the parasite in vitro and in vivo, including blockade of blood, liver, and transmission stages[1][4][6]. Nonetheless, therapeutic development faces challenges regarding selectivity due to conservation with human kinases and corresponding safety/toxicity concerns, necessitating careful optimization[3][4][7].

Other names

PI4KIIIβPfPI4KPlasmodium phosphatidylinositol 4-kinasephosphatidylinositol 4-kinase beta

Inhibition of kinase activity, preventing the synthesis of phosphatidylinositol 4-phosphate, leading to disruptions in membrane trafficking and parasite development through all major lifecycle stages[1][6].